Q3 2020 Sales Performance

Group: revenue breakdown 2019 Revenues of £33.8bn (+8% CER) Business Units Europe Regions Consumer (+2%) £7.2bn (21%) £9.0bn £8.1bn (24%) (27%) US £13.9bn (41%) Vaccines (+19%) £17.6bn (52%) Pharma (flat) Source: GSK Full year 2019 results release - February 2020 All growths at constant exchange rates (CER). Breakdown percentages are approximate gsk £11.8bn (35%) International 79 12

View entire presentation